Table 1 Task Force criteria for HD IL-2 therapy

 Clear cell histology - no papillary or granular features

1.21

 Adequate heart and lung function

3.57

 Performance Status

3.71

 Age (physiology ≤ 70 years)

4.64

 Prior nephrectomy

4.93

 Lack of CNS metastases (or treated)

5.42

 No prior TKI use

7.27

 MSKCC risk group

7.36

VLack of bone metastases

7.40

 Lack of liver metastases

8.56

 Lack of sarcomatoid histology

9.00

 CA IX status

10.78

 Other

11.00